Synthetic agonists of innate immune cells are of interest to immunologists due to their synthesis from well-defined materials, optimized activity, and monodisperse chemical purity. Recently we have reported the approach of Bystander-Assisted ImmunoTherapy (BAIT) that exploits the phenomenon of drug efflux in multi-drug-resistant cancers to elicit a localized anti-cancer immune response. In this context we examine the imidazoquinoline class of immunostimulants for susceptibility to drug efflux and begin to determine structural characteristics that drive efflux susceptibility for the Toll-Like Receptor agonist family of immmunsotimulants.

Citation Format: Amy E. Nielsen, Rock J. Mancini. An enzyme-directed pro-immunotherapeutic activated by muliti-drug resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-065.